Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Target Raised at HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by investment analysts at HC Wainwright from $200.00 to $202.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective suggests a potential upside of 132.10% from the company’s current price.

Other analysts have also recently issued research reports about the company. Morgan Stanley increased their target price on Mirum Pharmaceuticals from $137.00 to $152.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Stifel Nicolaus increased their price objective on shares of Mirum Pharmaceuticals from $136.00 to $156.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. TD Cowen lifted their price objective on shares of Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $150.19.

Mirum Pharmaceuticals Trading Up 1.5%

Shares of MIRM stock opened at $87.03 on Wednesday. Mirum Pharmaceuticals has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a current ratio of 2.86, a quick ratio of 2.74 and a debt-to-equity ratio of 1.28. The stock has a fifty day simple moving average of $89.53 and a two-hundred day simple moving average of $98.42.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The business had revenue of $185.72 million during the quarter, compared to analysts’ expectations of $178.07 million. During the same quarter in the previous year, the firm earned $0.05 earnings per share. Mirum Pharmaceuticals’s revenue was up 39.6% on a year-over-year basis. As a group, analysts forecast that Mirum Pharmaceuticals will post -1.32 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 658 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the transaction, the senior vice president directly owned 616 shares in the company, valued at approximately $61,600. This represents a 51.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $99.90, for a total value of $599,499.90. Following the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at $3,631,864.50. This represents a 14.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 96,659 shares of company stock valued at $9,604,100 in the last ninety days. Corporate insiders own 8.32% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently made changes to their positions in the business. Jupiter Topco LLC purchased a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $691,672,000. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $513,945,000. William Blair Investment Management LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at approximately $164,453,000. Janus Henderson Group PLC lifted its position in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at approximately $78,434,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.